Member Info for daringinvestor

Q - Why did the share price drop so sharply last year?
Answer - Someone’s ***** landed on the moon after applying MED2005

Q - if the phase 3 trial is unsuccessful what is the share price likely to be
Answer - £3.38

What a relief it is to have completed the phase 3a Study.
You never know what can happen so it's a big milestone as far as I am concerned.
We initially allocated 400 spaces for the OLE Study and have 450 participants. So again, extremely pleased with this.
Good luck all
Not long to go now!

"Now starcom got more products to sell, due to was an on going court case. "

wtf does this mean?

I don't post much on here but have been a shareholder now for around a year and a half, maybe just a little over.

I see a company that is punching well above it's weight and forming partnerships with some gigantic companies..It's not dependent on one company... and all the sectors are "growth" sectors... The growth potential is phenomenal when you look at all of this

The management have plenty of skin in the game so what's not to like? An absolute no brainer for me. It's a screaming "buy"

The only thing that will shift the share price upwards is excellent / good phase 3 results.

No amount of arguing or discussions will effect the outcome of the phase 3 results.
The trials are about to be completed with confirmation within the next two weeks. Then it'll all be down to getting the data unblinded and analyzing the results.
So save your energy and spend some time with your loved ones instead.
Good Luck all.

Indeed it is, especially at these prices

I plan to buy some more in the next day or two

So ...….UCB Pharma has struck a $2.5 billion (€2.2 billion) deal to acquire Ra Pharmaceuticals. The takeover will give UCB control of a phase 3 rival to Alexion’s Soliris that some analysts have tipped to rack up blockbuster sales.

So what are these block buster sale figures?
It's just over a billion dollars. Similar to MED...

I just hope the phase 3 trials exceed our expectations. If the data is excellent, we all could be in for a good surprise.

At last, an updated and much improved website.

bought at £4.80 today.
Will add more if it remains at this level next week.
Can’t argue with the div yield at a purchase price below £5!

Yep, trial will probably end by Mid October as there is a 4 week run in period too, where the baseline EF score is established.
Not long to go now.
Good luck all.

Giving a prediction with no timeline is totally worthless.
Anyway I see it has not dipped to the level you said (in March!!!) which is not to say it can’t do so in future however anyone who invested at that point would still have made some income from dividends.
Anyway I’m not in the business of making predictions. Good luck all. The company seems to have seen the worst of it IMHO.

If you actually read that paper on the phase 2 trials you can actually understand why the big pharma’s didn’t go for a deal.
It actually comes down to the fact that we need to show an increase in efficacy.
With the higher doses we should be able to achieve this. Not only that, but with the higher doses the residual amount of GTN should also help with the duration aspect too.
In the phase 2, 46 percent of respondents did not show an improvement on either placebo or Med.
14 percent of the placebo group showed an improvement.
Now when you compare that to the fact that this time round, 25 percent of the trial will be taking placebo and the fact that 80 percent of participants chose to carry on, it speaks volumes. Most likely pointing to the fact that we will indeed see an increase in efficacy. (Especially as there is no incentive , such as getting paid)
Even if we assume a worst case 50 percent placebo response rate, that would equate to 12.5 percent of the participants , however we have 80 percent selecting to carry on… I think it deserves pause for thought

Why the hell would I decide to carry on using a gel if I were not seeing some benefit?

I’m excited and look forward to the headline data.

Hahaha
Good one Thomas
Counteracting zwartkops like you said you would

Very amusing

Thomas - I can't access you-tube from where I am

Can you confirm again if I understood you right.

In the proactive interview, JB confirms the participants are not being paid for the open label part?

Thomas
That was the FIRST thing I thought of when I heard of the 80 percent that were following on with the treatment..

If they are NOT being paid, then this in my mind changes the picture considerably

Cast your minds back.
It was Thornton and Ross ( STADA ) that was dragging their feet with filing of the regulatory dossier and it was only really filed (if my memory serves me correct) in July after all discussions had been finished and FUM had made the decision to go it alone.
Now we see the similarities again when it comes to responding to the MHRA… and it coincides with yet again another milestone.
I don’t think it’s a coincidence
It all hangs on good phase 3 data. The increased doses should (I believe) have the desired effect and show increased efficacy

Excellent news
Another potential pathway for our tech
Intellectual property to be jointly owned
All costs covered
What’s not to like!!

When was this chat? any links?

So whenever he says it’s going down, it actually goes up.
This excellent for us shareholders!

The IC article assumes a pessimistic case of 230 million pounds per annum by 2028 and 500 million dollars in the most optimistic case. I think it is important to point out that this forecast was based on "prescription" only scenario.
The figures do not account for the over the counter scenario which was estimated as 650 million dollars (or thereabouts) on top of the prescription sales.If we assume the 230 million dollars as the pessimistic case and half of 650 million dollars as the pessimistic case for OTC, we still arrive at a figure in excess of 500 million dollars from which a royalty would be paid to FUM if thats the route the company chooses.
I personally believe the asset and with it the company should be sold as we have not had much luck when it comes to licensing deals and companies honouring their licensing commitments. The lowest risk to all investors would be to sell the asset/company once we get the phase 3 results which should hopefully show that MED2005 is a first line therapy for ED for a significant proportion of men.